“MMS plays a key role in bringing innovative and much-needed therapies to the marketplace, and because of this, we work to operate with a sense of urgency. As experts in pharmaceutical services, MMS is well-poised to now include the latest technology with IT expertise from Sage IT. Intelligent automation and bot development through this relationship will allow clinical trial sponsor teams to be more productive; shifting their focus to decision making versus the processing steps involved in data collection, analysis, and reporting,” said Kelly J. Hill, Executive Director, Global Project & Account Management, MMS Holdings.
“We are consistently pushing ourselves and our teams to revisit the old way and create innovative, new paths in the industry, and this is just one of the many ways that MMS is redefining the CRO experience,” HIll added.
“In this industry, you can’t slow down, and this mutually-beneficial relationship between MMS and Sage IT reflects the strong values, rigorous selection process, high standards, and clear communications that have maintained the partnership over the past decade,” said Aravind Kashyap, CEO, Sage IT. “Our goal is to make human and machine interaction smart through cognitive automation, and together MMS and Sage IT are accomplishing that.”
Last month, MMS released Automatiqc™ as a configurable tool to improve document quality and reduce the time for report development through the use of intelligent automation (IA). This was one of the many technological successes supported by the partnership with Sage IT.
“Measuring productivity in the pharmaceutical service industry is critical. Building efficiencies to reduce drug development costs have been an industry focus for a long time, and there is a need to quantify the value added by these innovations, or where there is resistance, the impact of delaying the implementation of an innovative service model or technology,” said Hill. “Key performance indicators (KPIs) related to productivity are a key in driving smart changes. These KPIs need to be clearly defined in a way that is meaningful to the functional lines, offering transparency into the process and resulting in actionable takeaways.”
Innovations related to clinical trial data planning, collection, analysis, and reporting has been a focus at MMS since inception in 2006. For more details, visit: www.mmsholdings.com
MMS is an award-winning, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company was named Most Outstanding CRO in the 2019 Biotechnology Awards and Best Global CRO in the 2018 International Life Sciences Awards. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.